Show simple item record

Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload

dc.contributor.authorZhou, Lanen_US
dc.contributor.authorGiacherio, Donald A.en_US
dc.contributor.authorCooling, Lauraen_US
dc.contributor.authorDavenport, Robertson D.en_US
dc.date.accessioned2010-06-01T22:43:41Z
dc.date.available2010-06-01T22:43:41Z
dc.date.issued2005-07en_US
dc.identifier.citationZhou, Lan; Giacherio, Donald; Cooling, Laura; Davenport, Robertson D. (2005). "Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload." Transfusion 45(7): 1056-1063. <http://hdl.handle.net/2027.42/75697>en_US
dc.identifier.issn0041-1132en_US
dc.identifier.issn1537-2995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75697
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15987348&dopt=citationen_US
dc.description.abstractTransfusion-associated circulatory overload (TACO) occurs when the transfusion rate or volume exceeds the capacity of a compromised cardiovascular system. Characteristic symptoms and signs associated with TACO are neither sensitive nor specific. B-natriuretic peptide (BNP) is a 32-amino-acid polypeptide secreted from the cardiac ventricles in response to ventricular volume expansion and pressure overload. This study was performed to explore the usage of BNP in the differential diagnosis of TACO. STUDY DESIGN AND METHODS: Pre- and posttransfusion BNP levels were determined in 21 patients with suspected TACO and 19 control patients. The BNP was considered significant if the posttransfusion-to-pretransfusion ratio was at least 1.5 and the posttransfusion BNP level was at least 100 pg per mL. RESULTS: The BNP test has a sensitivity and specificity of 81 and 89 percent, respectively, in diagnosis of TACO. It has a positive predictive value of 89 percent, a negative predictive value of 81 percent, and an accuracy of 87 percent. In logistic regression analysis, BNP was found to have significant predictive power independent of other clinical variables in models predicting which patients had TACO. CONCLUSIONS: Our study suggests that in patients who present symptoms suggestive of TACO, BNP can be a useful adjunct marker in confirming volume overload as the cause of acute dyspnea and symptoms related to cardiovascular compromise.en_US
dc.format.extent199121 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2005 American Association of Blood Banksen_US
dc.titleUse of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overloaden_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumFrom The University of Michigan Medical School, Ann Arbor, Michigan.en_US
dc.identifier.pmid15987348en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75697/1/j.1537-2995.2005.04326.x.pdf
dc.identifier.doi10.1111/j.1537-2995.2005.04326.xen_US
dc.identifier.sourceTransfusionen_US
dc.identifier.citedreferenceAudet AM, Popovsky MA, Andrzejewski C. Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology 1996; 12: 87 - 9.en_US
dc.identifier.citedreferenceSazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30: 583 - 90.en_US
dc.identifier.citedreferencePopovsky MA. Transfusion-related acute lung injury (TRALI). In: Popovsky MS, editor. Transfusion reactions. 2nd ed. Bethesda: American Association of Blood Banks; 2001. p. 155 - 70.en_US
dc.identifier.citedreferenceNakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 1995; 96: 1280 - 7.en_US
dc.identifier.citedreferenceYoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464 - 9.en_US
dc.identifier.citedreferenceMaeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825 - 32.en_US
dc.identifier.citedreferenceStein BC, Levin R. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998; 135: 914 - 23.en_US
dc.identifier.citedreferenceHolmes SJ, Espiner BA, Richards AM, et al. Renal, endocrine and haemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91 - 6.en_US
dc.identifier.citedreferenceKrishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274 - 9.en_US
dc.identifier.citedreferenceWei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation 1993; 88: 1004 - 9.en_US
dc.identifier.citedreferenceYamamoto K, Butnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988 - 94.en_US
dc.identifier.citedreferenceOgawa T, Linz W, Stevenson M. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 1996; 93: 2059 - 67.en_US
dc.identifier.citedreferenceHasegawa K, Fujiwara H, Doyama K. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993; 88: 372 - 80.en_US
dc.identifier.citedreferenceDavies M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994; 343: 440 - 4.en_US
dc.identifier.citedreferenceDao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379 - 85.en_US
dc.identifier.citedreferenceMcCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: an analysis from the Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416 - 22.en_US
dc.identifier.citedreferenceMaisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161 - 7.en_US
dc.identifier.citedreferenceDe Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone [review]. Chest 2004; 125: 652 - 68.en_US
dc.identifier.citedreferenceKleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2005; 44 :1774 - 89.en_US
dc.identifier.citedreferenceCooling L. Transfusion-related acute lung injury. JAMA 2002; 288: 315 - 6.en_US
dc.identifier.citedreferenceMcCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians [review]. Rev Cardiovasc Med 2003; 4: 72 - 80.en_US
dc.identifier.citedreferenceGobinet-Georges A, Valli N, Helene F, et al. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000; 38: 519 - 23.en_US
dc.identifier.citedreferenceDanielson CF, Rothenberger S, Wilson S, et al. Suspected transfusion reactions associated with an increase in respiratory rate. Transfusion 2003; 43: 22S.en_US
dc.identifier.citedreferenceBurgher AH, Aslan D, Laudi N, et al. Use of brain natriuretic peptide to evaluate transfusion-related acute lung injury. Transfusion 2004; 44: 1533 - 4.en_US
dc.identifier.citedreferenceCheung BM, Kumana CR. Natriuretic peptides: relevance in cardiac disease. JAMA 1998; 280: 1983 - 4.en_US
dc.identifier.citedreferencede Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316 - 22.en_US
dc.identifier.citedreferenceHunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47: 287 - 96.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.